アブストラクト
Japanese
| Title | IPMN国際診療ガイドライン - 次期改訂に向けて - |
|---|---|
| Subtitle | 〔特集〕グローバルな視点からみた膵疾患update |
| Authors | 大塚隆生1), 田中雅夫2) |
| Authors (kana) | |
| Organization | 1)鹿児島大学大学院医歯学総合研究科消化器・乳腺甲状腺外科, 2)下関市立市民病院外科 |
| Journal | 膵臓 |
| Volume | 36 |
| Number | 4 |
| Page | 238-244 |
| Year/Month | 2021 / |
| Article | 報告 |
| Publisher | 日本膵臓学会 |
| Abstract | 「要旨」: 2022年に本邦で開催される国際膵臓学会にあわせて膵管内乳頭粘液性腫瘍(intraductal papillary mucinous neoplasm of the pancreas : IPMN)国際診療ガイドラインの3回目の改訂作業が行われる予定である. 改訂される可能性がある以下のポイントについて述べた. (1)形態分類 : 混合型の定義と意義の確認, (2)組織亜型分類 : 好酸性細胞型の独立, (3)悪性診断 : 上皮内癌の表記法, (4)悪性を疑う所見(high risk stigmata とworrisome features)のアルゴリズムでの位置づけ : 超音波内視鏡(EUS)による評価の位置づけ, (5)悪性を疑う所見(high risk stigmataとworrisome features)の内容 : 結節高基準の再検討, (6)分枝型の経過観察法 : 併存通常型膵癌を考慮した経過観察法の提唱, (7)IPMN切除後の残膵経過観察 : 非腸型IPMN切除後の残膵通常型膵癌発症と主膵管型IPMN切除後の膵管内播種機序による残膵再発. |
| Practice | 臨床医学：内科系 |
| Keywords | IPMN, 国際診療ガイドライン, 併存膵癌, 経過観察, 切除, Guidelines, Pancreatic ductal adenocarcinoma, Surveillance, Resection |
English
| Title | International consensus guidelines for the management of IPMN of the pancreas - For the next revision |
|---|---|
| Subtitle | |
| Authors | Takao OHTSUKA1), Masao TANAKA2) |
| Authors (kana) | |
| Organization | 1)Department of Digestive Surgery, Breast and Thyroid Surgery, Graduate School of Medical Sciences, Kagoshima University, 2)Department of Surgery, Shimonoseki City Hospital |
| Journal | Journal of the Japan Pancreas Society |
| Volume | 36 |
| Number | 4 |
| Page | 238-244 |
| Year/Month | 2021 / |
| Article | Report |
| Publisher | Japan Pancreas Society |
| Abstract | The third revision of the International Consensus Guidelines for the management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas will be discussed during the 26th Meeting of the International Association of Pancreatology 2022 in Japan. There are 7 points to be discussed. 1) Morphological aspects; definition and significance of mixed type IPMN. 2) Subtype classification; independent of oncocytic type. 3) Pathological diagnosis; non-invasive carcinoma and high-grade dysplasia, and the definition of malignancy. 4) Modification of the algorithm for the management of branch duct IPMN. 5) Modification of the factors of high-risk stigmata and worrisome features; threshold of the height of mural nodules. 6) Modification of the surveillance protocol of branch duct IPMN considering possible development of concomitant pancreatic ductal adenocarcinoma (PDAC). 7) Surveillance protocol after resection of IPMN focusing on the remnant pancreas; possible development of concomitant PDAC after resection of non-intestinal IPMN and monoclonal skip lesions after resection of main duct IPMN. |
| Practice | Clinical internal medicine |
| Keywords | IPMN, Guidelines, Pancreatic ductal adenocarcinoma, Surveillance, Resection |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Tanaka M, Chari S, Adsay V, et al. International con-sensus guidelines for management of intraductal pap-illary mucinous neoplasms and mucinous cystic neo-plasms of the pancreas. Pancreatology 2006;6:17-32.
- 2) Tanaka M, Fernandez-del Castillo C, Adsay V, et al. International consensus guidelines 2012 for the man-agement of IPMN and MCN of the pancreas. Pancrea-tology 2012;12:183-97.
- 3) Tanaka M, Fernandez-del Castillo C, Kamisawa T, et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pan-creas. Pancreatology 2017;17:738-53.
- 4) 金 俊文, 潟沼朗生, 豊永啓翔, 他. IPMNの形態分類(分枝型, 主膵管型, 混合型). 胆と膵 2020;41:1183-7.
- 5) Shimizu Y, Hijioka S, Hirono S, et al. New model for predicting malignancy in patients with intraductal papillary mucinous neoplasm. Ann Surg 2020;272:155-62.
残りの16件を表示する
- 6) Matthaei H, Norris AL, Tsiatis AC, et al. Clinicopa-thological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 2012;255:326-33.
- 7) Ideno N, Ohtsuka T, Kono H, et al. Intraductal papil-lary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 2013;258:141-51.
- 8) Date K, Ohtsuka T, Fujimoto T, et al. Molecular evi-dence for monoclonal skip progression in main duct intraductal papillary mucinous neoplasms of the pan-creas. Ann Surg 2017;265:969-77.
- 9) Basturk O, Esposito I, Fukushima N. Pancreatic intra-ductal papillary mucinous neoplasm. In:WHO Classifi-cation of Tumours Editorial Board. WHO Classifica-tion of Tumours. Digestive System Tumours. 5th ed. Lyon:IARC Press, 2019:310-8.
- 10) 日本膵臓学会編. 膵癌取扱い規約. 第7版増補版. 東京:金原出版, 2020:71-103.
- 11) Singhi AD, Wood LD, Parks E, et al. Recurrent rear-rangements in PRKACA and PRKACB in intraductal oncocytic papillary neoplasms of the pancreas and bile duct. Gastroenterology 2020;158:573-82.
- 12) Sadakari Y, Ohuchida K, Nakata K, et al. Invasive car-cinoma derived from the nonintestinal type intraduc-tal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery 2010;147:812-7.
- 13) Omori Y, Ono Y, Tanino M, et al. Pathways of pro-gression from intraductal papillary mucinous neo-plasm to pancreatic ductal adenocarcinoma based on molecular features. Gastroenterology 2019;156:647-61.
- 14) Omori Y, Ono Y, Kobayashi T, et al. How does intesti-nal-type intraductal papillary mucinous neoplasm emerge? CDX2 plays a critical role in the process of intestinal differentiation and progression. Virchows Arch 2020;477:21-31.
- 15) Miyasaka Y, Ohtsuka T, Tamura K, et al. Predictive factors for the metachronous development of high-risk lesions in the remnant pancreas after partial pan-createctomy for intraductal papillary mucinous neo-plasm. Ann Surg 2016;263:1180-7.
- 16) Jang JY, Park T, Lee S, et al. Proposed nomogram pre-dicting the individual risk of malignancy in the pa-tients with branch duct type intraductal papillary mu-cinous neoplasms of the pancreas. Ann Surg 2017;266:1062-8.
- 17) European Study Group on Cystic Tumours of the Pan-creas. European evidence-based guidelines on pan-creatic cystic neoplasms. Gut 2018;67:789-804.
- 18) 真口宏介. 現行のHigh-risk stigmataは適切か? 胆と膵 2020;41:1307-11.
- 19) 真口宏介, 大塚隆生. IPMN登録事業と前向き予後調査. 竹原徹郎, 金井隆典, 他編. Annual Review消化器2016. 東京:中外医学社, 2016:163-7.
- 20) Date K, Ohtsuka T, Nakamura S, et al. Surveillance of patients with intraductal papillary mucinous neo-plasm with and without pancreatectomy with special reference to the incidence of concomitant pancreatic ductal adenocarcinoma. Surgery 2018;163:291-9.
- 21) Gotoh Y, Ohtsuka T, Nakamura S, et al. Genetic as-sessment of recurrent pancreatic high-risk lesions in the remnant pancreas:metachronous multifocal lesion or local recurrence? Surgery 2019;165:767-74.
